LENZ Therapeutics (LENZ) Cash from Financing Activities (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Cash from Financing Activities data on file, last reported at $14000.0 in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 68.18% year-over-year to $14000.0 in Q1 2026; TTM through Mar 2026 was $149.7 million, a 438.97% increase from a year earlier, with the FY2025 full-year figure at $149.7 million, down 24.75% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $14000.0, down from $122.6 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for LENZ reached as high as $171.3 million in Q1 2024 and fell as low as -$2.1 million in Q2 2024.
• Historically, Cash from Financing Activities has averaged $28.7 million across 5 years, with a median of $244000.0 in 2022.
• Across the five-year window, Cash from Financing Activities slumped 883.2% in 2023 and surged 231249.06% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $244000.0 in 2022, then slumped by 883.2% to -$1.9 million in 2023, then soared by 102.77% to $53000.0 in 2024, then jumped by 231249.06% to $122.6 million in 2025, then sank by 99.99% to $14000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $14000.0 in Q1 2026, $122.6 million in Q4 2025, and $598000.0 in Q3 2025.